Clinical

Dataset Information

0

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors


ABSTRACT: To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

DISEASE(S): Adenocarcinoma,Colorectal Cancer (crc),Small Cell Lung Cancer,Colorectal Cancer,Small Cell Lung Carcinoma,Head And Neck Squamous Cell Carcinoma (hnscc),Lung Neoplasms,Small Cell Lung Cancer (sclc),Non Small Cell Lung Cancer Squamous (nsclc-sq),Prostatic Neoplasms,Squamous Cell Carcinoma Of Head And Neck,Pancreatic Ductal Adenocarcinoma (pdac),Metastatic Castration-resistant Prostate Cancer (mcrpc),Colorectal Neoplasms,Prostate Cancer,Carcinoma, Non-small-cell Lung,Head And Neck Cancer

PROVIDER: 2294936 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2258148 | ecrin-mdr-crc
2015-11-11 | GSE66999 | GEO
2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress
2011-11-21 | GSE32035 | GEO
2022-03-11 | GSE198136 | GEO
2014-02-04 | GSE54621 | GEO
2014-02-04 | E-GEOD-54621 | biostudies-arrayexpress
2022-11-16 | GSE212521 | GEO
| 2144055 | ecrin-mdr-crc
2012-04-11 | E-GEOD-37180 | biostudies-arrayexpress